Symposium to Honor Scientific Legacy of the Late Stanley J. Korsmeyer
The Dana-Farber Cancer Institute will host an international symposium on "Cell Death and Cancer," in Boston on January 25-26, 2007.
The Dana-Farber Cancer Institute in collaboration with the American Association for Cancer Research is sponsoring the Stanley J. Korsmeyer Symposium, January 25-26, 2007, at the Conference Center at Harvard Medical School in Boston, MA.
The symposium, “Cell Death and Cancer: Opportunities for Therapeutic Intervention,” honors the distinguished career of the late Stanley Korsmeyer, who was a Howard Hughes Medical Institute investigator at the Dana-Farber Cancer Institute. He died in March 2005 after a long struggle with lung cancer.
Korsmeyer was recognized as an international leader in the field of programmed cell death, and his numerous published research papers opened new vistas in a quartet of disciplines, including immunology, hematology, oncology and genetics.
Korsmeyer's pioneering work on the regulation of programmed cell death, also known as apoptosis, led to the identification of many of the key genetic mechanisms that govern cell death and survival. His research also defined the role of cell death in the pathogenesis of human diseases, including lymphomas and other cancers.
The symposium, which is also being sponsored by the International Cell Death Society, will highlight a cascade of discoveries surrounding the regulation of apoptosis and its relationship to cancer. Speakers will also address the new opportunities for therapeutic intervention stemming from this rapidly growing field of research.
Welcome and Memorial Tribute to Stanley J. Korsmeyer
6:00 p.m. to 6:15 p.m.
Edward J. Benz, President and Chief Executive Officer, Dana-Farber Cancer Institute
David G. Nathan, President Emeritus, Dana-Farber Cancer Institute
6:15 p.m. to 7:00 p.m.
H. Robert Horvitz, HHMI and Massachusetts Institute of Technology, Cambridge, MA
7:15 p.m. to 8:00 p.m.
Friday, January 26, 2007
7:30 a.m. to 8:30 a.m.
Session 1: Cell Death
8:30 a.m. to 10:00 a.m.
Hermann Steller, The Rockefeller University, New York, NY
Junying Yuan, Harvard Medical School, Boston, MA
10:00 a.m. to 10:30 a.m.
Session 2: Cancer
10:30 a.m. to 12:30 p.m.
Craig B. Thompson, University of Pennsylvania, Philadelphia, PA
Eileen P. White, Howard Hughes Medical Institute, Center for Advanced Biotechnology and Medicine, Piscataway, NJ
John C. Reed, The Burnham Institute, La Jolla, CA
12:30 p.m. to 1:15 p.m.
Session 3: Therapeutic Intervention
1:15 p.m. to 2:15 p.m.
Gregory L. Verdine, Harvard University, Cambridge, MA
Loren D. Walensky, Dana-Farber Cancer Institute, Boston, MA
2:15 p.m. to 2:35 p.m.
Session 3: Therapeutic Intervention (Continued)
2:35 p.m. to 4:00 p.m.
Xiaodong Wang, HHMI and UT Southwestern Medical Center, Dallas, TX
Stephen W. Fesik, Abbott Laboratories, Abbott Park, IL